This study aimed to identify a panel of biomarkers that would increase the precision of distinguishing patients in relapse compared to sNfL alone. Findings identified four blood protein including sNFL, uPA, hK8 and DSG3 that accurately distinguished relapse from remission in RRMS patients, providing an improved biomaker panel for monitioring disease activity beyond traditional measures.
Read MoreThis study shows IFN-B treatment in relapsing remitting multiple sclerosis increases transitional and regualatory B-cell, enhancing IL-10 production. Findings highlight IFN-B's role in regulating immune responses, with significant implications for MS therapy and disease management.
Read MoreThis study evaluated serum cytokine profiles for their utility to determine the heterogeneous responses to interferon (IFN)-β treatment in patients with multiple sclerosis (MS). Findings revealed that six cytokine-based subgroups with varied IFN-B treatment responses. Some subsets showed poor outcomes, while others had reduced relapses, highlighting immune heterogeneity linked to therapy effectiveness.
Read More